Extraordinary General Meeting of Active Biotech AB
05 4월 2019 - 1:00AM
PRESS RELEASE Lund Sweden, April 4 2019 - Active Biotech (NASDAQ
STOCKHOLM: ACTI) Extraordinary General Meeting of Active Biotech
An Extraordinary General Meeting of Active Biotech
AB (publ) was held on April 4, 2019.
In accordance with the Board of Directors'
proposal, it was resolved to approve sale of the company's property
Forskaren 1 in Lund, Sweden, to a newly formed investor collective
led by the real estate company Estea AB.
The purchase price amounts to SEK 275 million,
which corresponds to the property's book value. Closing is expected
to take place on April 5, 2019.
Lund April 4, 2019
Active Biotech AB (publ)
For further information, please
contact:
Helén Tuvesson, CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA, an immunotherapy, in development for cancer
indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Extraordinary General Meeting of
Active Biotech AB
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024